Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: Results from a national patient register

Annals of the Rheumatic Diseases

Volumn 65, Issue 7, 2006, Pages 895-898

  Hyrich, K ^a   Symmons, D ^a   Watson, K ^a   Silman, A ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CYCLOSPORIN A; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE;

ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; HUMAN; HYPERTENSION; LUNG DISEASE; MAJOR CLINICAL STUDY; PEPTIC ULCER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ASTHMA; COHORT STUDIES; DATABASES, FACTUAL; DEPRESSION; FEMALE; HUMANS; HYPERTENSION; IMMUNOLOGIC FACTORS; LUNG DISEASES; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NEOPLASMS; PEPTIC ULCER; SOCIETIES, MEDICAL; TUBERCULOSIS;

EID: 33745700487     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.043158     Document Type: Article

References (20)

1. Wolfe F, Mifchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
2. Gordon P, West J, Jones H, Gibson T. A 10 year prospective follow-up of patients with rheumatoid arthritis 1986-96. J Rheumatol 2001;28:2409-15.
3. Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002;46:2010-19.
4. Berkanovic E, Hurwicz ML. Rheumatoid arthritis and comorbidity. J Rheumatol 1990;17:888-892.
5. Gabriel SE, Crowson CS, O'Fallon WM. Comorbidity in arthritis. J Rheumatol 1999;26:2475-9.
6. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003;42:617-621.
7. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-70.
8. Slifman NR, Gershon SK, Lee J-H, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor a-neutralizing agents. Arthritis Rheum 2003;48:319-24.
9. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N Engl J Med 2001;345:1098-104.
10. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montera MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
11. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
12. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807-11.
13. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8.
14. Silman A, Symmons D, Scott DG, Griffiths I. British Society for Rheumatology Biologies Register. Ann Rheum Dis 2003;62(suppl 2):ii28-ii29.
15. British Society for Rheumatology. Update of BSR guidelines for prescribing TNF bloclcers in adults with rheumatoid arthritis: https://www.msecportal.org/portal/editorial/PublicPages/bsr/536883013/ FinalTNFforRAguideline.pdf, 2004.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
17. Prevoo ML, 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
18. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
19. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
20. Sany J, Bourgeois P, Saraux A, Durieux S, Lafuma A, Daures JP, et al. Characteristics of patients with rheumatoid arthritis in France: a study of 1109 patients managed by hospital based rheumatologists. Ann Rheum Dis 2004;63:1235-40.